{"id":"acei-continuation","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Dry cough"},{"rate":"5-10","effect":"Dizziness"},{"rate":"2-5","effect":"Hyperkalemia"},{"rate":"0.1-0.5","effect":"Angioedema"},{"rate":"3-5","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ACE inhibitors work by inhibiting the angiotensin-converting enzyme, which is responsible for converting inactive angiotensin I into the potent vasoconstrictor angiotensin II. By blocking this conversion, ACEIs reduce peripheral vascular resistance, decrease blood pressure, and reduce the workload on the heart. This mechanism also leads to decreased aldosterone secretion, reducing sodium and water retention.","oneSentence":"ACEI continuation refers to the ongoing use of angiotensin-converting enzyme inhibitors to block the conversion of angiotensin I to angiotensin II, thereby reducing vasoconstriction and lowering blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:29:19.638Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure"},{"name":"Post-myocardial infarction"},{"name":"Diabetic nephropathy"}]},"trialDetails":[{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT04506372","phase":"NA","title":"Management of Angiotensin Inhibitors During the Perioperative Period","status":"TERMINATED","sponsor":"UMC Utrecht","startDate":"2020-09-11","conditions":"Surgery, Angiotensin Hypertension, Perioperative Complication","enrollment":342},{"nctId":"NCT03957161","phase":"NA","title":"ACEi ARB Withdrawal in CKD Patients","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2023-11","conditions":"Chronic Kidney Disease, Blood Pressure, Angiotensin-converting Enzyme Inhibitor","enrollment":""},{"nctId":"NCT01669434","phase":"PHASE4","title":"Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2015-06-01","conditions":"Hypotension on Induction","enrollment":291},{"nctId":"NCT04351581","phase":"NA","title":"Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With and Without COVID-19","status":"COMPLETED","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2020-05-18","conditions":"Covid-19","enrollment":78},{"nctId":"NCT04353596","phase":"PHASE4","title":"Stopping ACE-inhibitors in COVID-19","status":"COMPLETED","sponsor":"Medical University Innsbruck","startDate":"2020-04-20","conditions":"SARS-CoV-2, COVID-19","enrollment":216},{"nctId":"NCT04338009","phase":"NA","title":"Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2020-03-31","conditions":"COVID-19","enrollment":152},{"nctId":"NCT04329195","phase":"PHASE3","title":"ACE Inhibitors or ARBs Discontinuation in Context of COVID-19 Pandemic","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-04-09","conditions":"History of Cardiovascular Disease Treated With RAS Blockers and With SARS-CoV-2 Infection","enrollment":44},{"nctId":"NCT02200822","phase":"PHASE4","title":"Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients","status":"COMPLETED","sponsor":"Hasselt University","startDate":"2014-07","conditions":"Heart Failure (HF)","enrollment":80},{"nctId":"NCT02096406","phase":"PHASE2","title":"Outcomes of Angiotensin Converting Enzyme Inhibitor Management Strategies Prior to Coronary Artery Bypass","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2014-04","conditions":"Coronary Artery Disease","enrollment":126},{"nctId":"NCT02859311","phase":"PHASE4","title":"A Pilot Feasibility Study in Recovered Heart Failure","status":"UNKNOWN","sponsor":"Royal Brompton & Harefield NHS Foundation Trust","startDate":"2016-04","conditions":"Heart Failure","enrollment":50},{"nctId":"NCT01867047","phase":"NA","title":"ACE-Inhibitor Effects on Total Hip and Knee Arthroplasty Patients","status":"TERMINATED","sponsor":"Duke University","startDate":"2013-06","conditions":"Adverse Effects of Angiotensin-converting-enzyme Inhibitors, Hypotension","enrollment":59}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":63,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["quinapril","Accupril","perindopril","Aceon","ramipril"],"phase":"marketed","status":"active","brandName":"ACEI continuation","genericName":"ACEI continuation","companyName":"University of Nebraska","companyId":"university-of-nebraska","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ACEI continuation refers to the ongoing use of angiotensin-converting enzyme inhibitors to block the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Used for Hypertension, Heart failure with reduced ejection fraction, Post-myocardial infarction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}